SteadyMed Celebrates Phenomenal People With Pulmonary Hypertension During PH Awareness Month With Launch of New Informational...
November 17 2016 - 8:30AM
SteadyMed Ltd. (Nasdaq:STDY) today announced that it has launched a
new website, BePHenomenal.com, dedicated to educating and
empowering people living with pulmonary hypertension (PH) to live
their healthiest and most PHenomenal lives. SteadyMed is also
sponsoring a Thunderclap, as well as a photo and video drive to
recognize the strength and beauty within this community.
BePHenomenal.com will offer expert lifestyle information
customized for people with PH, including exercise videos, healthy
recipes and stories from people living with PH about how they
manage their condition and refuse to let PH define them. People
living with PH are encouraged to visit the site and register to
receive updates as new information is added.
“Initial diagnosis and management of PH can be quite
overwhelming to the patient, family or caregiver,” said Patricia
Gresha, PH Nurse Practitioner and Program Coordinator, Fresno
Pulmonary Hypertension Program. “BePHenomenal.com will help provide
patients and their caregivers with health and wellness tools
customized to their unique needs."
“As someone living with PH, it is important that I find ways to
live my best life every day and carry out my personal motto, ‘it’s
a great day to be alive,’” said Carol Bowling, PH patient. “The
BePHenomenal.com website provides information about maintaining a
healthy lifestyle by sharing wellness and exercise tips from PH
patients and experts familiar with PH. I am inspired by this
PHenomenal community, and am grateful to SteadyMed for continuing
to help our voices be heard.”
As part of PH awareness activities in November, SteadyMed is
inviting people with PH and their loved ones to join a Thunderclap
celebrating the unique strength and beauty within the PH community.
The Thunderclap will be issued on Thursday, Nov. 17 at 12 p.m. ET,
and those interested in adding their voice in support can do so by
signing up here or by pasting this link into your
browser https://www.thunderclap.it/en/projects/49440-celebrate-your-phenomself.
Thunderclap is an online tool that helps people rally together to
spread a message on social media at the same time.
SteadyMed is also introducing a photo and video drive on Twitter
and Facebook encouraging those affected by PH to share what they
are thankful for this holiday season using the hashtag
#PHenomSelf.
“SteadyMed is dedicated to supporting the PH community, and we
hope that BePHenomenal.com helps empower and inspire this community
to live their most PHenomenal lives,” said Marylyn Rigby, Senior
Director, Investor Relations and Marketing at SteadyMed. “We are
always excited to honor the incredible people in the PH community.
We are especially grateful to do so during Pulmonary Hypertension
Awareness month and look forward to sharing more amazing stories
from members of this community through our Thunderclap and photo
and video drive.”
PH is a condition defined as high blood pressure in the lungs.
One form of PH, pulmonary arterial hypertension (PAH), is a
progressive and life-changing chronic disease. Symptoms, which
worsen over time and significantly impact patients’ lives, can
include shortness of breath, dizziness and fatigue. There is no
cure for the disease, which can become life-threatening within a
few years if left untreated.
About SteadyMedSteadyMed Ltd.
is a specialty pharmaceutical company focused on the development of
drug products to treat orphan and high value diseases with unmet
parenteral delivery needs. The company's lead drug product
candidate is Trevyent®, a development stage drug product that
combines SteadyMed's PatchPump® technology with treprostinil, a
vasodilatory prostacyclin analogue to treat pulmonary arterial
hypertension (PAH). SteadyMed intends to commercialize Trevyent in
the U.S. and has signed an exclusive license and supply agreement
with Cardiome Pharma Corp. for the commercialization of Trevyent in
Europe, Canada and the Middle East. SteadyMed has offices in San
Ramon, California and Rehovot, Israel. For additional information
about SteadyMed please visit www.steadymed.com.
Forward Looking Statements
This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements include, among
others, statements about the company's ability to advance its
development-stage product candidates, including Trevyent.
Forward-looking statements reflect the company's current views with
respect to certain current and future events and are subject to
various risks, uncertainties and assumptions that could cause
actual results to differ materially. Risks and uncertainties
include, but are not limited to, the risk that Trevyent does not
demonstrate clinical superiority to existing parenteral
treprostinil products, that Trevyent is not approved for
commercialization by the FDA, that Trevyent is not granted orphan
drug exclusivity, and the risk that drug development involves a
lengthy and expensive process with uncertain outcome. The risks,
uncertainties and assumptions referred to above are discussed in
detail in our reports filed with the Securities and Exchange
Commission, including our Quarterly Report on Form 10-Q filed on
November 14, 2016. The company does not undertake to publicly
update or revise any forward-looking statements to reflect events
or circumstances that may arise after the date hereof except as may
be required by law.
Contact:
Marylyn Rigby
Senior Director, Investor Relations and Marketing
925-272-4999
mrigby@steadymed.com
STEADYMED LTD. (NASDAQ:STDY)
Historical Stock Chart
From Aug 2024 to Sep 2024
STEADYMED LTD. (NASDAQ:STDY)
Historical Stock Chart
From Sep 2023 to Sep 2024